| abstract |
Polymorphic crystalline forms of Ibandronate sodium were found, referred to hereinafter as polymorphic Form α, Form β, Form ε, Form δ, Form γ and Form ζ. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms, to pharmaceutical compositions comprising them, as well as their use. |